Durata Therapeutics to Host Conference Call & Webcast on December 11, 2012 at 9:00AM ET to Present Preliminary Top-line Resul...
December 10 2012 - 4:39PM
Business Wire
Durata Therapeutics, Inc. (NASDAQ:
DRTX) today announced that it will host a conference call and
webcast at 9:00am Eastern Time on Tuesday, December 11, 2012 to
present preliminary top-line results from its DISCOVER 1
(“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”) Phase 3 study of dalbavancin,
which is under investigation for the treatment of acute bacterial
skin and skin structure infections (ABSSSI) caused by susceptible
gram-positive bacteria.
To access the call, please dial 866-632-4021 for participants in
the U.S. or Canada and 404-991-3968 for international callers,
reference passcode: 79502265. A replay of the call may be accessed
through December 25, 2012 by dialing 800-585-8367 for callers in
the U.S. and Canada and (404) 537-3406 for international callers,
reference passcode: 79502265. The conference call will also be
webcast live on Durata’s website, www.duratatherapeutics.com.
About Dalbavancin
Dalbavancin is an intravenous antibiotic product candidate under
investigation for once-weekly dosing, which we believe may
facilitate the treatment of patients with ABSSSI in both the
in-patient and out-patient settings, potentially reducing the
length of a patient’s hospital stay or avoiding hospital admission
altogether, with an impact on the overall cost of care for these
patients.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the
development and commercialization of novel therapeutics for
patients with infectious diseases and acute illnesses. Durata has
completed two global Phase 3 trials with its lead product
candidate, dalbavancin, for the treatment of patients with acute
bacterial skin and skin structure infections, or ABSSSI.
Forward-looking statements
Statements contained in this press release contain
forward-looking statements that involve substantial risks and
uncertainties. All statements, other than statements of historical
facts, contained in this press release, including statements
regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and
objectives of management, are forward-looking statements. The words
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,”
“plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Forward-looking statements in this press release include statements
about the potential benefits of dalbavancin. Actual results may
differ materially from those indicated by these forward-looking
statements as a result of various important factors, including
those discussed in the “Risk Factors” section of our most recent
quarterly report on Form 10-Q, which is on file with the SEC and is
also available on our website. In addition, any forward-looking
statements represent our views only as of today and should not be
relied upon as representing our views as of any subsequent date.
While we may elect to update these forward-looking statements at
some point in the future, we specifically disclaim any obligation
to do so, even if our views change. Therefore, you should not rely
on these forward-looking statements as representing our views as of
any date subsequent to today.
(MM) (NASDAQ:DRTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:DRTX)
Historical Stock Chart
From Jul 2023 to Jul 2024